phrykt

Shuttle Pharmaceuticals Holdings, Inc. (SHPH): who owns it and who trades it

As of Nov 6, 2026, SHPH insiders reported 5 open-market sales worth $505K and 6 purchases worth $182K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Hrt Financial Lp (10% owner), with $505K.

Latest filing Nov 6, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

In the last 12 months, SHPH insiders reported $182K of open-market purchases and $505K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$182K
6 trades, 1 people
Sales, 12 months
$505K
5 trades, 1 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Jul 14, 2026
Filed Jul 15, 2026

Purchases and sales by month

$505K$505KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jul 14, 2026Hrt Financial Lp10% ownerSale82,116$4.48$368KForm 4
Jul 13, 2026Hrt Financial Lp10% ownerSale1,033$4.67$4.8KForm 4
Jul 10, 2026Hrt Financial Lp10% ownerPurchase731$3.11$2.3KForm 4
Jul 9, 2026Hrt Financial Lp10% ownerPurchase8,266$3.38$27.9KForm 4
Jul 8, 2026Hrt Financial Lp10% ownerSale18,531$3.52$65.2KForm 4
Jul 7, 2026Hrt Financial Lp10% ownerSale10,580$3.33$35.2KForm 4
Jul 6, 2026Hrt Financial Lp10% ownerSale9,022$3.51$31.7KForm 4
Jul 2, 2026Hrt Financial Lp10% ownerPurchase7,851$3.54$27.8KForm 4
Jul 1, 2026Hrt Financial Lp10% ownerPurchase3,959$3.30$13.1KForm 4
Jun 30, 2026Hrt Financial Lp10% ownerPurchase6,755$3.23$21.8KForm 4
Jun 29, 2026Hrt Financial Lp10% ownerPurchase25,836$3.44$88.9KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Hrt Financial Lp10% owner$182K$505KJul 14, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

SHPH short interest

Low short interest. 0.3% of SHPH shares are sold short: about 1 share in 319. Over the last 12 reports the number of shares short went down 97%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 14,956 SHPH shares were sold short, 0.3% of the shares outstanding, down 52.2% from the report before. At the average daily volume of 27,864 shares, buying them all back would take about 1.0 trading days (days to cover).

Shares short, % of all shares

0.31%May 15Oct 309.03%

Days to cover

1.0May 15Oct 301.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202614,9560.31%-52%27,8641.0
Oct 15, 202631,3070.66%+76%54,0731.0
Sep 30, 202617,7900.37%-19%35,1321.0
Sep 15, 202621,9750.39%-44%27,7581.0
Aug 31, 202639,3310.70%-26%74,9601.0
Aug 14, 202652,9200.95%-6%219,1571.0
Jul 31, 202656,3791.01%-87%736,9491.0
Jul 15, 2026429,6607.68%+213%7.54M1.0
Jun 30, 2026137,2732.46%+311%4.26M1.0
Jun 15, 202633,4040.60%-85%313,9311.0
May 29, 2026225,6744.04%-49%279,7161.0
May 15, 2026441,2457.89%+280%3.20M1.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Shuttle Pharmaceuticals Holdings company events

Shuttle Pharmaceuticals Holdings filed 22 reports on Form 8-K in the last 12 months, 8 of them about an important change (leadership, auditor, listing). The latest was on Nov 6, 2026.

  1. Nov 6, 2026AuditorChanges in Registrant’s Certifying Accountant. Filing
  2. Oct 22, 2026AuditorChanges in Registrant’s Certifying Accountant. Filing
  3. Sep 16, 2026SharesSold new shares outside a public offering. Filing
  4. Sep 11, 2026VoteReported shareholder vote results. Filing
  5. Sep 2, 2026AnnouncementShuttle Pharmaceuticals Holdings, Inc. is announcing the postponement of its previously announced special meeting of stockholders from its currently scheduled date and time on Thursday, September 3, 2026, at 11:00 a.m. Filing
  6. Sep 1, 2026AgreementShuttle Pharmaceuticals Holdings, Inc. and United Dogecoin Inc., a wholly-owned subsidiary of the Company as a result of the consummation on May 6, 2026 of that certain transaction contemplated by the Agreement and Plan of Merger dated April 30, 2026, by and among the Company, United Dogecoin and… Filing
  7. Aug 28, 2026ListingShuttle Pharmaceuticals Holdings, Inc. received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that, as a result of the Company’s delay in filing its Quarterly Report on Form 10-Q for the period ended June 30, 2026 with the Securities and… Filing
  8. Aug 17, 2026DealAmended an earlier report. Of the Original 8-K. Pursuant to Item 9.01 of the Original 8-K, the Company was to file (i) the financial statements of UDC required by Item 9.01(a) and (ii) the pro forma financial information required by Item 9.01(b), in each case as an amendment to the Original 8-K no later than 74 calendar days… Filing
  9. Jul 1, 2026AnnouncementIs hereby incorporated by reference into this Item 7.01. Filing
  10. Jun 11, 2026SharesChanged the rights of its shareholders. Filing
  11. May 27, 2026VoteReported shareholder vote results. Filing
  12. May 7, 2026LeadershipIn connection with the consummation of the Merger and pursuant to the Merger Agreement, the Board of Directors of Shuttle approved the appointment of Ryan Trasolini, Chief Executive Officer of the Company, as Co-Chief Executive Officer of the Acquiror, effective at the Effective Time. Filing
  13. May 1, 2026AgreementShuttle Pharmaceuticals Holdings, Inc., a Delaware corporation, entered into an Agreement and Plan of Merger with Shuttle Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Shuttle and United Dogecoin Inc., a Delaware corporation. Filing
  14. Mar 10, 2026AgreementShuttle Pharmaceuticals Holdings, Inc. priced its recently announced public offering of 2,238,800 shares of the Company’s common stock par value $0.00001 per share, and pre-funded warrants to purchase up to 4,761,200 shares of Common Stock for aggregate gross proceeds of approximately $3.5 million… Filing
  15. Feb 17, 2026ResultsReleased financial results. Filing
  16. Feb 2, 2026LeadershipAs previously disclosed in our Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on March 12, 2025, in connection with Mr. Christoper Cooper’s appointment to the position of interim co-Chief Executive Officer, on March 11, 2025, Shuttle Pharmaceuticals Holdings… Filing
  17. Jan 12, 2026LeadershipThe Board of Directors of Shuttle Pharmaceuticals Holdings, Inc. appointed Ms. Yuying Liang, CPA as Chief Financial Officer of the Company. Filing
  18. Dec 29, 2025AgreementShuttle Pharmaceuticals Holdings, Inc. entered into a First Amendment to Asset Purchase Agreement with 1563868 B.C. Ltd., a Canadian limited corporation and the Company’s wholly owned subsidiary, 1542770 BC Ltd., a Canadian limited corporation, and ZhiTian (Andy) Zhang, an individual residing in… Filing
  19. Nov 28, 2025LeadershipTimothy Lorber resigned as Chief Financial Officer of Shuttle Pharmaceuticals Holdings, Inc., effective immediately. Filing
  20. Nov 26, 2025DealThe disclosure set forth under Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. Filing
  21. Nov 21, 2025AgreementAs previously disclosed by the Company in its Current Report on Form 8-K, filed with the U.S. Securities and Exchange Commission on October 21, 2025, on October 15, 2025, Shuttle Pharmaceuticals Holdings, Inc. received a letter from Theradex Systems, Inc., providing written notice of termination of… Filing
  22. Nov 17, 2025ListingShuttle Pharmaceuticals Holdings, Inc. reported stockholders’ equity of $1.39 million in its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2025, and, as a result, was not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on the Nasdaq… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Shuttle Pharmaceuticals Holdings financials

Questions about Shuttle Pharmaceuticals Holdings, Inc. (SHPH) stock

Are SHPH insiders buying or selling?

In the last 12 months, SHPH insiders reported 6 open-market purchases worth $182K and 5 sales worth $505K. The latest trade was on Jul 14, 2026. See every trade.

What is the short interest in SHPH?

As of Oct 30, 2026, 14,956 SHPH shares were sold short, 0.3% of the shares outstanding, down 52.2% from the report before. At the average daily volume of 27,864 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.